Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume 56, Issue 9, Pages 2650-2659
Publisher
Informa UK Limited
Online
2015-01-09
DOI
10.3109/10428194.2015.1004168
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Determination of chitinases family during osteoclastogenesis
- (2014) Michelino Di Rosa et al. BONE
- The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group
- (2013) Evangelos Terpos et al. AMERICAN JOURNAL OF HEMATOLOGY
- The Role of Denosumab for Prevention of Skeletal-Related Complications in Multiple Myeloma
- (2013) Kelly Hageman et al. ANNALS OF PHARMACOTHERAPY
- The effects of bortezomib on bone disease in patients with multiple myeloma
- (2013) Mohamad Mohty et al. CANCER
- Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma
- (2013) R. Shao et al. CARCINOGENESIS
- International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease
- (2013) Evangelos Terpos et al. JOURNAL OF CLINICAL ONCOLOGY
- Chitinase 3-like 1 Regulates Cellular and Tissue Responses via IL-13 Receptor α2
- (2013) Chuan Hua He et al. Cell Reports
- Role of Chitin and Chitinase/Chitinase-Like Proteins in Inflammation, Tissue Remodeling, and Injury
- (2011) Chun Geun Lee et al. Annual Review of Physiology
- A Gene Expression-Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment
- (2011) P. Wu et al. CLINICAL CANCER RESEARCH
- Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of Glioblastoma
- (2011) Ralph A. Francescone et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- (2011) David H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- The Role of Bisphosphonates in Multiple Myeloma: Mechanisms, Side Effects, and the Future
- (2011) S. Pozzi et al. ONCOLOGIST
- Bone Disease From Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: Pathogenesis, Interventions, and Future Opportunities
- (2011) Alex R. Minter et al. SEMINARS IN HEMATOLOGY
- Targeting the bone microenvironment in multiple myeloma
- (2010) G. David Roodman JOURNAL OF BONE AND MINERAL METABOLISM
- Identification of proteins secreted by human osteoblastic cells in culture
- (2010) Julia S. Johansen et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial
- (2010) Peter Gimsing et al. LANCET ONCOLOGY
- The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group
- (2010) E Terpos et al. LEUKEMIA
- Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease
- (2010) E Terpos et al. LEUKEMIA
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
- (2009) M. Fulciniti et al. BLOOD
- RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases
- (2009) Evangelos Terpos et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Plasma YKL-40: a potential new cancer biomarker?
- (2009) Julia S Johansen et al. Future Oncology
- Diurnal, Weekly, and Long-Time Variation in Serum Concentrations of YKL-40 in Healthy Subjects
- (2008) J. S. Johansen et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions
- (2008) Robert Coleman et al. CANCER TREATMENT REVIEWS
- Chitinase 3-Like-1 (CHI3L1): A Putative Disease Marker at the Interface of Proteomics and Glycomics
- (2008) Frederick D. Coffman CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
- High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients
- (2008) Anne K. Mylin et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Serum YKL-40 and bone marrow angiogenesis in multiple myeloma
- (2008) Anne K. Mylin et al. INTERNATIONAL JOURNAL OF CANCER
- Pathogenesis of myeloma bone disease
- (2008) G D Roodman LEUKEMIA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started